Summary

The Middle East and Africa pemphigus vulgaris market is expected to reach USD 36.30 million by 2032 from USD 20.88 million in 2024, growing at a CAGR of 7.3% in the forecast period of 2025 to 2032.
Market Segmentation:
Middle East and Africa Pemphigus Vulgaris Market Segmentation, By Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy), Countries (Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Bahrain, Israel, Oman, Qatar, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032

Overview of Middle East and Africa Pemphigus Vulgaris Market Dynamics:

Driver

• Emerging treatment options for pemphigus vulgaris

Restraint
• Stringent regulatory guidelines for pemphigus vulgaris drug approval
Opportunity
Increasing demand for personalized medicine

Market Players:

The key market players operating in the Middle East and Africa pemphigus vulgaris market are listed below:

• Sanofi (France)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GSK plc. (U.K.)
• AstraZeneca (U.K.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Abbvie Inc. (U.S.)
• Amgen Inc (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Fresenius Kabi AG (Germany)
• GRIFOLS SA (Spain)
• Cipla Health Ltd (India)
• SUNPHARMA.NS (India)
• Zydus Group (India)

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW 40
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 42
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 CURRENCY AND PRICING 47
2.5 DBMR TRIPOD DATA VALIDATION MODEL 48
2.6 MULTIVARIATE MODELLING 51
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.8 DBMR MARKET POSITION GRID 54
2.9 MARKET END USER COVERAGE GRID 55
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 64
4.1 PESTAL ANALYSIS 65
4.2 PORTERS FIVE FORCES ANALYSIS 66
4.3 PATENT ANALYSIS 67
4.3.1 PATIENT FLOW DIAGRAM 68
4.3.2 KEY PRICING STRATEGIES 69
4.3.3 FUTURE THERAPIES 69
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES 70
4.4 MIDDLE EAST AND AFRICA CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET 72
4.5 SUPPLY CHAIN ECOSYSTEM 78
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET 80
4.7 EPIDEMIOLOGY: MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET 83
4.7.1 INCIDENCE BY GENDER 83
4.7.2 TREATMENT RATE 83
4.7.3 MORTALITY RATE 83
4.7.4 PATIENT TREATMENT SUCCESS RATES 84
5 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET: REGULATIONS 85
6 MARKET OVERVIEW 91
6.1 DRIVERS 93
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 93
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS 94
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS 95
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS 96
6.2 RESTRAINTS 97
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL 97
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES 98
6.3 OPPORTUNITIES 99
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 99
6.3.2 INCREASING HEALTHCARE FACILITIES 100
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT 101
6.4 CHALLENGES 102
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS 102
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES 103
7 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 104
7.1 OVERVIEW 105
7.2 TREATMENT 108
7.3 DIAGNOSIS 110
8 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 111
8.1 OVERVIEW 112
8.2 ADULTS 115
8.3 GERIATRIC 115
8.4 PEDIATRIC 116
9 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER 117
9.1 OVERVIEW 118
9.2 HOSPITALS 121
9.3 SPECIALTY CLINICS 121
9.4 RESEARCH INSTITUTES 122
9.5 OTHERS 122
10 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 123
10.1 OVERVIEW 124
10.2 HOSPITALS PHARMACY 127
10.3 RETAIL PHARMACY 127
10.4 ONLINE PHARMACY 128
11 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY REGION 129
11.1 MIDDLE EAST AND AFRICA 131
11.1.1 SAUDI ARABIA 135
11.1.2 EGYPT 139
11.1.3 U.A.E. 142
11.1.4 SOUTH AFRICA 145
11.1.5 ISRAEL 149
11.1.6 BAHRAIN 152
11.1.7 KUWAIT 156
11.1.8 OMAN 159
11.1.9 QATAR 162
11.1.10 REST OF MIDDLE EAST AND AFRICA 165
12 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 166
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
13 SWOT ANALYSIS 167
14 COMPANY PROFILE 168
14.1 MERCK AND CO. INC. 168
14.1.1 COMPANY SNAPSHOT 168
14.1.2 REVENUE ANALYSIS 168
14.1.3 COMPANY SHARE ANALYSIS 169
14.1.4 PRODUCT PORTFOLIO 169
14.1.5 RECENT DEVELOPMENTS 170
14.2 SANOFI 171
14.2.1 COMPANY SNAPSHOT 171
14.2.2 REVENUE ANALYSIS 171
14.2.3 COMPANY SHARE ANALYSIS 172
14.2.4 PRODUCT PORTFOLIO 172
14.2.5 RECENT DEVELOPMENT 173
14.3 REGENERON PHARMACEUTICALS INC. 174
14.3.1 COMPANY SNAPSHOT 174
14.3.2 REVENUE ANALYSIS 174
14.3.3 COMPANY SHARE ANALYSIS 175
14.3.4 PRODUCT PORTFOLIO 175
14.3.5 RECENT DEVELOPMENTS 176
14.4 JOHNSON & JOHNSON SERVICES, INC. 177
14.4.1 COMPANY SNAPSHOT 177
14.4.2 REVENUE ANALYSIS 177
14.4.3 COMPANY SHARE ANALYSIS 178
14.4.4 PRODUCT PORTFOLIO 178
14.4.5 RECENT DEVELOPMENT 179
14.5 ASTRAZENECA 180
14.5.1 COMPANY SNAPSHOT 180
14.5.2 REVENUE ANALYSIS 180
14.5.3 COMPANY SHARE ANALYSIS 181
14.5.4 PRODUCT PORTFOLIO 181
14.5.5 RECENT DEVELOPMENT 182
14.6 ABBVIE INC. 183
14.6.1 COMPANY SNAPSHOT 183
14.6.2 REVENUE ANALYSIS 183
14.6.3 PRODUCT PORTFOLIO 184
14.6.4 RECENT DEVELOPMENT 185
14.7 ACCORD HEALTHCARE 187
14.7.1 COMPANY SNAPSHOT 187
14.7.2 PRODUCT PORTFOLIO 187
14.7.3 RECENT DEVELOPMENT 187
14.8 AMGEN INC. 188
14.8.1 COMPANY SNAPSHOT 188
14.8.2 REVENUE ANALYSIS 188
14.8.3 PRODUCT PORTFOLIO 189
14.8.4 RECENT DEVELOPMENT 190
14.9 ARTIVA BIOTHERAPEUTICS, INC. 191
14.9.1 COMPANY SNAPSHOT 191
14.9.2 REVENUE ANALYSIS 191
14.9.3 PRODUCT PIPELINE PORTFOLIO 192
14.9.4 RECENT DEVELOPMENT 192
14.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 193
14.10.1 COMPANY SNAPSHOT 193
14.10.2 PRODUCT PORTFOLIO 193
14.10.3 RECENT DEVELOPMENT 193
14.11 BAXTER 194
14.11.1 COMPANY SNAPSHOT 194
14.11.2 REVENUE ANALYSIS 194
14.11.3 PRODUCT PORTFOLIO 195
14.11.4 RECENT DEVELOPMENT 195
14.12 BIOXPRESS THERAPEUTICS SA 196
14.12.1 COMPANY SNAPSHOT 196
14.12.2 PRODUCT PORTFOLIO 196
14.12.3 RECENT DEVELOPMENT 196
14.13 CABALETTA BIO INC. 197
14.13.1 COMPANY SNAPSHOT 197
14.13.2 REVENUE ANALYSIS 197
14.13.3 PRODUCT PORTFOLIO 197
14.13.4 RECENT DEVELOPMENT 198
14.14 CIPLA HEALTH LTD 199
14.14.1 COMPANY SNAPSHOT 199
14.14.2 PRODUCT PORTFOLIO 199
14.14.3 RECENT DEVELOPMENTS 199
14.15 CELLTRION 200
14.15.1 COMPANY SNAPSHOT 200
14.15.2 REVENUE ANALYSIS 200
14.15.3 PRODUCT PORTFOLIO 201
14.15.4 RECENT DEVELOPMENTS 202
14.16 CSL 203
14.16.1 COMPANY SNAPSHOT 203
14.16.2 REVENUE ANALYSIS 203
14.16.3 PRODUCT PORTFOLIO 204
14.16.4 RECENT DEVELOPMENT 204
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD. 205
14.17.1 COMPANY SNAPSHOT 205
14.17.2 REVENUE ANALYSIS 205
14.17.3 PRODUCT PORTFOLIO 206
14.17.4 RECENT DEVELOPMENT 206
14.18 F. HOFFMANN- LA ROCHE LTD. 207
14.18.1 COMPANY SNAPSHOT 207
14.18.2 REVENUE ANALYSIS 207
14.18.3 PRODUCT PORTFOLIO 208
14.18.4 RECENT DEVELOPMENT/NEWS 208
14.19 FRESENIUS KABI AG 210
14.19.1 COMPANY SNAPSHOT 210
14.19.2 REVENUE ANALYSIS 210
14.19.3 PRODUCT PORTFOLIO 211
14.19.4 RECENT DEVELOPMENT 211
14.20 GSK PLC 213
14.20.1 COMPANY SNAPSHOT 213
14.20.2 REVENUE ANALYSIS 213
14.20.3 PRODUCT PORTFOLIO 214
14.20.4 RECENT DEVELOPMENT 214
14.21 GRIFOLS, S.A. 216
14.21.1 COMPANY SNAPSHOT 216
14.21.2 REVENUE ANALYSIS 216
14.21.3 PRODUCT PORTFOLIO 217
14.21.4 RECENT DEVELOPMENT 217
14.22 INCYTE 218
14.22.1 COMPANY SNAPSHOT 218
14.22.2 REVENUE ANALYSIS 218
14.22.3 PRODUCT PORTFOLIO 219
14.22.4 RECENT DEVELOPMENT 219
14.23 NOVARTIS AG 220
14.23.1 COMPANY SNAPSHOT 220
14.23.2 REVENUE ANALYSIS 220
14.23.3 PRODUCT PORTFOLIO 221
14.23.4 RECENT DEVELOPMENT 221
14.24 LILLY 222
14.24.1 COMPANY SNAPSHOT 222
14.24.2 REVENUE ANALYSIS 222
14.24.3 PRODUCT PORTFOLIO 223
14.24.4 RECENT DEVELOPMENT 223
14.25 OCTAPHARMA AG 224
14.25.1 COMPANY SNAPSHOT 224
14.25.2 REVENUE ANALYSIS 224
14.25.3 PRODUCT PORTFOLIO 225
14.25.4 RECENT DEVELOPMENT/NEWS 225
14.26 PFIZER INC. 226
14.26.1 COMPANY SNAPSHOT 226
14.26.2 REVENUE ANALYSIS 226
14.26.3 PRODUCT PORTFOLIO 227
14.26.4 RECENT DEVELOPMENT 227
14.27 RAKSHIT DRUGS PVT. LTD 228
14.27.1 COMPANY SNAPSHOT 228
14.27.2 PRODUCT PORTFOLIO 228
14.27.3 RECENT DEVELOPMENT 229
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD. 230
14.28.1 COMPANY SNAPSHOT 230
14.28.2 REVENUE ANALYSIS 230
14.28.3 PRODUCT PORTFOLIO 231
14.28.4 RECENT DEVELOPMENT 231
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD 232
14.29.1 COMPANY SNAPSHOT 232
14.29.2 REVENUE ANALYSIS 232
14.29.3 PRODUCT PORTFOLIO 233
14.29.4 RECENT DEVELOPMENT 233
14.30 ZYDUS GROUP 235
14.30.1 COMPANY SNAPSHOT 235
14.30.2 REVENUE ANALYSIS 235
14.30.3 PRODUCT PORTFOLIO 236
14.30.4 RECENT DEVELOPMENT 237
15 QUESTIONNAIRE 238
16 RELATED REPORTS 241